# Republic Health Insurance Fund (RFZO)

Source: https://onco.cc/institutions/rfzo-serbia/  
OnCo record `rfzo-serbia` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Serbia's compulsory health insurer. The law makes it pay in full for the examination and treatment of cancer and for palliative care, and it sets the national medicines list; the 2020 to 2022 cancer programme describes innovative cancer medicines on a restricted list C prescribed only through tertiary hospitals.

## Summary

The Republic Health Insurance Fund administers compulsory health insurance under the Law on Health Insurance (Official Gazette 25/2019, amended 2023 and 2025). Article 131 lists the services paid in full from compulsory insurance, among them examination and treatment of malignant diseases and palliative care. Under article 66 the Fund adopts the medicines list, which must include essential medicines in line with the WHO Model List, with the Government's consent; a medicine not on the list can still be provided when it is medically necessary, under conditions the Fund sets. Article 69 gives the Fund 90 days from a complete application to decide whether a medicine meets the criteria for the list. The Fund's website refused plain requests on 11 November 2026, gave an empty reply on 17 November 2026, and was read through the Internet Archive. The coordinates are an approximate Belgrade city point.

The 2020 to 2022 cancer control programme describes how cancer medicines reach patients: innovative medicines financed by the Fund are given to patients who meet set medical criteria under list C, which is administered only through tertiary institutions, and it named a lack of biological medicines and immunotherapy on the list as a weakness. A notice of 16 December 2024 on the Fund's home page says it has made it possible for patients on innovative breast cancer medicines to receive part of their therapy in general hospitals instead of clinical centres. The EFPIA Patients W.A.I.T. Indicator 2025 survey, compiled by IQVIA and published in 2026, counted 8 of the 56 cancer medicines authorised centrally in the EU in 2021 to 2024 as available in Serbia on 5 January 2026 (14%, against an EU average of 51%), 13% of the 8 with full public availability and 88% with limited availability on an individual-patient basis, and described two forms of limited availability in Serbia: a listed medicine bought in a limited number of packs a year with committees approving each patient, and an unlisted medicine supplied free on a named-patient basis, such as under article 9 of the rulebook that allows hospitals to buy non-reimbursed medicines for patients with no other option on the list.

## Fields

- Kind: Institution
- Last checked: 2026-11-11
- Also known as: RFZO; Republički fond za zdravstveno osiguranje; Republic Fund for Health Insurance; Serbian Health Insurance Fund
- City: Belgrade, RS
- Type: government
- Website: https://www.rfzo.rs

## Sources

- Republic Health Insurance Fund (read through the Internet Archive, capture of 17 July 2026): https://web.archive.org/web/20260717211617/https://rfzo.rs/
- Law on Health Insurance, articles 66, 69 and 131 (Serbian, consolidated text, paragraf.rs): https://www.paragraf.rs/propisi/zakon_o_zdravstvenom_osiguranju.html
- Programme for Improving Cancer Control 2020 to 2022, section on diagnosis and treatment (Serbian, PDF): https://www.iccp-portal.org/system/files/plans/SRB_B5_s21_PROGRAM%20UNAPREDJENJA%20KONTROLE%20RAKA%20U%20REPUBLICI%20SRBIJI%202020%202022%20%281%29.pdf
- EFPIA Patients W.A.I.T. Indicator 2025 survey, pages 22, 23, 27 and 68 (PDF): https://www.efpia.eu/media/mnfdwzax/efpia-patients-wait-indicator-2025.pdf

## Connected records

- institutions: [Medicines and Medical Devices Agency of Serbia (ALIMS)](https://onco.cc/institutions/alims-serbia/), [Ministry of Health of the Republic of Serbia](https://onco.cc/institutions/serbia-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/rfzo-serbia.json